References
- Dalakas, M. C. (2015). Immunopathogenesis of myasthenia gravis and the role of immunotherapies. Nature Reviews Neurology, 11(9), 465–476.
https://doi.org/10.1038/nrneurol.2015.129 - Evoli, A., & Padua, L. (2013). Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmunity Reviews, 12(9), 931–935.
https://doi.org/10.1016/j.autrev.2013.03.002 - Gilhus, N. E. (2016). Myasthenia Gravis. The New England Journal of Medicine, 375(26), 2570–2581.
- Gilhus, N. E., Tzartos, S., Evoli, A., Palace, J., Burns, T. M., & Verschuuren, J. J. (2019). Myasthenia gravis. Nature Reviews Disease Primers, 5(1), 30.
https://doi.org/10.1038/s41572-019-0079-y - Howard, J. F., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., … & Sanders, D. B. (2022). Safety and efficacy of efgartigimod in generalized myasthenia gravis (ADAPT): A phase 3, randomised, placebo-controlled trial. The Lancet Neurology, 21(6), 526–536.
https://doi.org/10.1016/S1474-4422(22)00100-6 - Meuth, S. G., Meisel, A., Wiendl, H., & Ruck, T. (2022). Independent risk factors for myasthenic crisis and disease exacerbation in myasthenia gravis. Journal of Neuroinflammation, 19(1), 89.
- National Blood Authority (Australia). Criteria for the clinical use of intravenous immunoglobulin in Australia. Canberra: NBA; 2024.
- Narayanaswami, P., Sanders, D. B., Wolfe, G. I., Benatar, M., Cea, G., Evoli, A., … & Guidon, A. C. (2021). International consensus guidance for management of myasthenia gravis: 2021 update. Neurology: Clinical Practice, 11(4), e473–e487.
https://doi.org/10.1212/CPJ.0000000000001106 - Pharmaceutical Benefits Advisory Committee (PBAC). Public Summary Documents: Efgartigimod and other MG submissions, 2024–2025. Canberra: PBAC.
- Rowland, L. P., & Pedley, T. A. (2010). Merritt’s Neurology (12th ed.). Lippincott Williams & Wilkins.
- Sanders, D. B., Wolfe, G. I., Benatar, M., Evoli, A., Gilhus, N. E., Illa, I., & Narayanaswami, P. (2008). International consensus guidance for management of myasthenia gravis: Executive summary. Neurology, 70(7), 565–573.
https://doi.org/10.1212/01.wnl.0000280579.50739.d1 - Sanders, D. B., Wolfe, G. I., Benatar, M., et al. (2016). International consensus guidance for management of myasthenia gravis: Executive summary. Neurology, 87(4), 419–425
- Therapeutic Goods Administration (TGA). Australian Public Assessment Reports and Product Information: Ravulizumab (2023), Efgartigimod (2025), Rozanolixizumab (2025), Zilucoplan (2025). Canberra: TGA.
- Wolfe, G. I., Kaminski, H. J., Aban, I. B., et al. (2016). Randomized trial of thymectomy in myasthenia gravis. New England Journal of Medicine, 375(6), 511–522.
https://doi.org/10.1056/NEJMoa1602489 - Zhang, B., Tzartos, J. S., Belimezi, M., et al. (2012). Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Archives of Neurology, 69(4), 445–451.
https://doi.org/10.1001/archneurol.2011.2025
Language: English
Page range: 35 - 43
Published on: May 18, 2026
Published by: Australasian Neuroscience Nurses Association
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Related subjects:
© 2026 J. Stofmeel, published by Australasian Neuroscience Nurses Association
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.